Target Name: GH2
NCBI ID: G2689
Review Report on GH2 Target / Biomarker Content of Review Report on GH2 Target / Biomarker
GH2
Other Name(s): GH2 variant 2 | GHB2 | GH-V | Growth hormone variant (isoform 2) | growth hormone 2 | Placental-specific growth hormone | growth hormone B2 | hGH-V | placental-specific growth hormone | Growth hormone 2 | Growth hormone 2, transcript variant 2 | Placenta-specific growth hormone | GHL | Growth hormone variant | SOM2_HUMAN | placenta-specific growth hormone | GHV

GH2: Potential Drug Targets and Biomarkers

GH2 (GH2 variant 2) is a protein that is expressed in the human placenta and has been shown to play a role in the development and maintenance of pregnancy. While the exact function of GH2 is not yet fully understood, research has identified several potential drug targets and biomarkers that may be associated with GH2.

GH2 is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling. GPCRs are characterized by aextracellular domain, a transmembrane segment, and an intracellular domain that contains a G protein and a regulatory protein. GH2 is a type of GPCR that is expressed in the placenta, and it is thought to play a role in the regulation of pregnancy.

One potential drug target for GH2 is the protein known as GLM-1 (Gestational Law of Mass). GLM-1 is a non-coding RNA molecule that is expressed in the placenta and is thought to play a role in the regulation of pregnancy outcomes. Studies have shown that GLM-1 levels are decreased in placenta of women with preterm labor, which may be a potential drug target for GH2.

Another potential drug target for GH2 is the protein known as CDK4 (Cyclin DK4). CDK4 is a transcription factor that is involved in the regulation of cell growth and differentiation. GH2 has been shown to interact with CDK4, which may suggest that GH2 may be a target for a drug that inhibits CDK4 activity.

GH2 has also been shown to interact with the protein known as TGF-β2 (Transforming Growth Factor 尾2). TGF-β2 is a cytokine that is involved in the regulation of cell growth and differentiation, andGH2 has been shown to interact with TGF-β2, which may suggest that GH2 may be a target for a drug that inhibits TGF-β2 activity.

In addition to these potential drug targets, GH2 has also been shown to be involved in the regulation of pregnancy outcomes. Studies have shown that GH2 levels are decreased in the placenta of women who have preterm birth, which may be a potential biomarker for GH2-related diseases.

GH2 has also been shown to play a role in the regulation of fetal development and growth. For example, GH2 has been shown to be involved in the regulation of cell proliferation and differentiation, as well as the formation of the neural tube.

While the exact function of GH2 is not yet fully understood, it is clear that it is involved in the regulation of pregnancy outcomes.GH2 has been shown to interact with several potential drug targets, including GLM-1, CDK4, and TGF-β2. These interactions suggest that GH2 may be a potential drug target for a variety of diseases.

In conclusion, GH2 is a protein that is expressed in the human placenta and has been shown to play a role in the development and maintenance of pregnancy. While the exact function of GH2 is not yet fully understood, research has identified several potential drug targets and biomarkers that may be associated with GH2. Further studies are needed to fully understand the role of GH2 in pregnancy and to develop effective treatments for GH2-related diseases.

Protein Name: Growth Hormone 2

Functions: Plays an important role in growth control. Its major role in stimulating body growth is to stimulate the liver and other tissues to secrete IGF-1. It stimulates both the differentiation and proliferation of myoblasts. It also stimulates amino acid uptake and protein synthesis in muscle and other tissues

The "GH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GHDC | GHITM | GHR | GHRH | GHRHR | GHRL | GHRLOS | GHSR | GID4 | GID8 | GIGYF1 | GIGYF2 | GIHCG | GIMAP1 | GIMAP1-GIMAP5 | GIMAP2 | GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3 | GJD4 | GK | GK2 | GK3 | GK5 | GKAP1 | GKN1 | GKN2 | GKN3P | GLA | GLB1 | GLB1L | GLB1L2 | GLB1L3 | GLC1C | GLCCI1 | GLCCI1-DT | GLCE | GLDC | GLDN | GLE1 | GLG1 | GLI1 | GLI2 | GLI3 | GLI4 | GLIDR | GLIPR1 | GLIPR1L1 | GLIPR1L2 | GLIPR2 | GLIS1 | GLIS2 | GLIS3 | GLIS3-AS1 | GLMN | GLMP | GLO1 | GLOD4 | GLOD5 | GLP1R | GLP2R